SweGaN wins commercial orders worth €2.3m
SweGaN, a European semiconductor manufacturer specialising in GaN-on-SiC epitaxial wafers, today announced that it has secured multiple new commercial framework agreements from customers across Europe, Asia, and the United States.
The orders received during the first four months of 2026 represent a total contract value of approximately €2.3m (SEK 25m) and will contribute to revenue over the next coming 6 to 18 months.
The new orders span a broad range of applications, including power devices for data centres and RF devices for defence, aerospace, and telecommunications. They reflect the growing interest and demand for SweGaN’s differentiated material technology and innovation capabilities.
“We are pleased to see the strong growth and commercial traction across a diverse global customer and application base,” said Jr-Tai Chen, CEO of SweGaN. “This indicates the recognition the market is showing to the value our material performance and tailored solutions can bring to their products and these design-in and design-win orders will propel our abilities to invest in capacity expansion and continued product innovation for the future”, Chen added.
In conjunction with this update, SweGaN also announces the appointment of Ulf Nolemo as chief commercial officer (CCO), effective May 1st, 2026. In this role, Nolemo will be responsible for leading SweGaN’s global commercial strategy, including sales & marketing activities, business development, and strategic customer partnerships.
Nolemo brings 30 years of experience from the semiconductor industry with a strong track record in scaling commercial operations and driving innovation across international markets. Ulf has previously held leading positions at industry leaders such as Ericsson, Wolfspeed, Macom, NXP, and Infineon.
“The appointment of a chief commercial officer marks an important step as we enter our next phase of growth,” said Jr-Tai Chen, CEO of SweGaN. “The industry experience and commercial leadership brought by our newly appointed CCO will be critical as global demand for our GaN epitaxial solutions continues to expand.
